LAKE FOREST, CA--(Marketwire - Dec 27, 2012) - TRIMEDYNE, INC. ("Trimedyne") (
Professor Costello will also conduct pre-clinical animal, cadaver and other testing at the Royal Melbourne Hospital and, when all of the regulatory requirements have been met, he and Dr. Cowles will conduct "pilot" clinical trials to confirm the results of using Urodyne's new laser and new, disposable, fiber-optic devices in the treatment of BPH, Urinary Incontinence, and Fecal Incontinence, as well as "pilot" clinical trials to confirm the results of using Hyperdyne's new laser and new, disposable fiber-optic devices in the treatment of Uncontrolled Hypertension, before commencing the above 300 patient clinical trials.
Professor Costello is one of the world's leading researchers in Urology and is the author or co-author of 165 Scientific Publications, has 14 Professional Appointments, received 7 Professional Honors and Awards, has 19 Professional Society Affiliations, has 33 Advisory and Membership Appointments, administered 25 Funded Research Programs, conducted 73 Invited Lectureships, managed 21 Course Directorships, authorized or co-authored 10 U.S. Patents, conducted 10 Fellowships and authored 13 Published Book Chapters and three Educational Publications.
Professor Costello established the Victorian Prostate Cancer Research Consortium, which became the National Prostate Cancer Foundation, the leading prostate cancer research organization in Australia. Professor Costello also directs a $15 million prostate cancer research program funded by the Government of Australia.
Trimedyne manufactures proprietary Holmium lasers and patented and patent pending fiber optic laser devices to treat a variety of medical conditions in minimally-invasive procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery. For product, press release, financial, SEC Reports and other information, please visit Trimedyne's website, http://www.trimedyne.com.
"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:
Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, including words like "believe", "expect", "may", "could" and others. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's current Form 10-K Report and subsequently filed SEC Reports. There is no assurance such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in the statements in such Reports, which Trimedyne has no obligation to update.